Mesoblast Ltd (ASX:MSB)

APAC company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - MSB

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - MSB

  • Market CapAUD0.000m
  • SymbolASX:MSB
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINAU000000MSB8

Company Profile

Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.Mesoblast Ltd is engaged in the development of biologic products for the broad field of regenerative medicine. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.

Latest MSB news

Currently there for this company. Visit our news hub for other news .